Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of ruxolitinib and
lenalidomide can help to control MF. The safety of this study drug combination will also be
studied.
Ruxolitinib is designed to stop certain proteins (called JAK1 and JAK2) that are found in MF
cells from sending signals that may lead to the growth of cancer cells.
Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth. This may decrease the
growth of cancer cells.